scholarly journals Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer

BMC Cancer ◽  
2006 ◽  
Vol 6 (1) ◽  
Author(s):  
Silvia Saviozzi ◽  
Francesca Cordero ◽  
Marco Lo Iacono ◽  
Silvia Novello ◽  
Scagliotti V Giorgio ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Gene Expression Profile ◽  
Reference Genes ◽  
Small Cell ◽  
Small Cell Lung ◽  
Accurate Normalization ◽  
Suitable Reference ◽  
Selection Of

scholarly journals P1.05-014 Stemness Gene Expression Profile of Tumorspheres from Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (1) ◽  
pp. S621-S622
Author(s):  
Alejandro Herreros Pomares ◽  
Silvia Calabuig Fariñas ◽  
Ester Munera Maravilla ◽  
Ana Blasco ◽  
Aminta Isabel Martinez ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

2021 ◽  
Vol 2021 ◽  
pp. 1-8
Author(s):  
Jingyao Li ◽  
Yang Qiu ◽  
Junxiu Yi ◽  
Xi Liu ◽  
Shixin Zhang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Mrna Expression ◽  
Chemotherapy Regimen ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Experimental Group ◽  
Selection Of

Objective. To investigate the clinical significance of the mRNA expression of RRM1, TUBB3, and ERCC1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens. Methods. Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared. Results. Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( P > 0.05 ). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909–0.5827, P = 0.0025 ). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine ( P = 0.025 ). In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment ( P = 0.0039 ). Conclusions. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.

Gene-expression profile of primary non-small cell lung cancer associated with brain metastasis: A prospective study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e18028-e18028
Author(s):  
Oscar Arrieta ◽  
David Saavedra-Perez ◽  
Alette Ortega ◽  
Claudia Rangel ◽  
Alejandro Aviles-Salas ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Prospective Study ◽  
Small Cell Lung Cancer ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Cell Lung Cancer ◽  
External Validation ◽  
Small Cell ◽  
Small Cell Lung

e18028 Background: Brain metastases (BM) occur in 30-50% of non-small cell lung cancer (NSCLC) patients and confer worse prognosis and quality of life. Better selection of in-risk patients through an accurate biomarker could improve the benefit of prophylactic therapies. The aim of this prospective study was to determine a gene-expression profile (GEP) of primary tumor (PT) associated with BM in patients with advanced NSCLC. Methods: From January 2009 to June 2011, patients with stage IV of NSCLC were evaluated. PT core biopsy was performed prior to any treatment and snap-frozen. Samples with tumor cellularity > 70% and RNA integrity number > 8 were chosen for RNA isolation. A cDNA microarray platform representing 33,297 genes was used to obtain GEPs. All patients received standard chemotherapy. BM were confirmed by magnetic resonance imaging. Non- and supervised hierarchical clustering methods were employed to identify GEPs. Results: A total of 29 patients were enrolled, 79.4% (23/29) were adenocarcinomas, and 20.6% have other histology. BM were present in 15 (51.7%) patients, 14 at diagnosis and 1 was developed at 5 months of follow-up. Clinical characteristics were similar for patients with and without BM. At non- and supervised analyses, 35 genes up and down regulated were evidenced in BM group. From these, 11 transcripts with proteomic functions previously associated with metastasis processes were identified. Conclusions: Our work provides valuable biological information for development of predictive biomarkers for metastatic brain tumors from primary NSCLC. External validation of our gene-expression signature in a different set of patients is warranted. [Table: see text]

scholarly journals Apoptosis Gene Expression Profile in Early-Stage non Small Cell Lung Cancer

2010 ◽  
Vol 13 (2) ◽  
pp. 47-52
Author(s):  
S Metodieva ◽  
R Cherneva ◽  
D Nikolova ◽  
G Genchev ◽  
D Petrov ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Gene Expression Profile ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung ◽  
Early Stage Nsclc ◽  
Apoptosis Gene

Apoptosis Gene Expression Profile in Early-Stage non Small Cell Lung CancerNon small cell lung cancer (NSCLC) is a highly aggressive malignancy with survival rates limited to some patients in early stages (I and II). Apoptosis resistance is a hallmark of solid tumors that is tightly concerned with their biology. We analyzed the expression of 84 apoptosis-related genes in a group of Bulgarian patients with early-stage NSCLC.RNA samples extracted from 12 early-stage NSCLC patients [five squamous cell carcinomas (SCC) and seven adenocarcinomas (AC)] and eight adjacent non neoplastic pulmonary tissues were used for gene expression analysis. We applied pathway-focused expression profiling of 84 apoptosis-related genes using real-time PCR.Apoptosis-related genes down regulated in NSCLC compared to non tumor lung tissue (p <0.05) included representatives of the tumor necrosis factor (TNF) ligand family [TNF superfamily 8 (TNFSF8)], caspase cascade (CASP8 and CASP10) and caspase recruitment domain (CARD) family (BCL10), the positive apoptosis regulator DAPK1 and BCL2 family member MCL1. The potential of apoptosis-related genes as prognostic and predictive markers should be validated in future studies.

scholarly journals Reference genes for gene expression studies on non-small cell lung cancer.

2009 ◽  
Vol 56 (2) ◽  
Author(s):  
Peter Gresner ◽  
Jolanta Gromadzinska ◽  
Wojciech Wasowicz
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Reference Genes ◽  
Small Cell ◽  
Stable Gene ◽  
Small Cell Lung ◽  
Expression Studies ◽  
Gene Expression Studies

The aim of this study was to test a panel of 6 reference genes in order to identify and validate the most suitable reference genes for expression studies in paired healthy and non-small cell lung cancer tissues. Quantitative real-time PCR followed by the NormFinder- and geNorm-based analysis was employed. The study involved 21 non-small cell lung cancer patients. The analysis of experimental data revealed HPRT1 as the most stable gene followed by RPLP0 and ESD. In contrast, GAPDH was found to be the least stable gene. HPRT1 together with ESD was revealed as the pair of genes introducing the least systematic error into data normalization. Validation by bootstrap random sampling technique and by normalizing exemplary gene expression data confirmed the results. Although HPRT1 and ESD may by recommended for data normalization in gene expression studies on non-small cell lung cancer, the suitability of selected reference genes must be unconditionally validated prior to each study.

Sign in / Sign up

Export Citation Format

Share Document